Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,323.00+0.70%ETH$2,476.87+0.33%GOLD$4,221.50+1.55%OIL$91.61+0.13%
Smart Investors Daily
SID Premium
AT

NASDAQ · ATHE

Alterity Therapeutics Limited

Healthcare · Biotechnology

$3.07

Up+$0.05 (+1.47%)

Updated Oct 9, 2026, 8:40 PM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.19M
P/E ratio
-4.93
Dividend yield
0.00%
52-week range
$3.04 – $5.89
Volume
34.37K
Avg. volume
14.18K

Price performance · ATHE

ATHE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 8, 2026

ATHE closed at $3.07 after 21 trading sessions, down 25.30% for the selected period.

Last close
$3.07
Period change
-25.30%
Period low
$3.07
Period high
$4.11
Daily close
View OHLC price history
ATHE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 8, 2026$3.21$3.3399$3.04$3.0734.37K
Oct 7, 2026$3.41$3.51$3.29$3.3219.34K
Oct 6, 2026$3.34$3.4574$3.22$3.3721.86K
Oct 5, 2026$3.2899$3.29$3.10$3.2254.64K
Oct 2, 2026$3.39$3.4588$3.25$3.4547.17K
Oct 1, 2026$3.53$3.57$3.38$3.4923.2K
Sep 30, 2026$3.47$3.87$3.4601$3.6530.35K
Sep 29, 2026$3.50$3.8924$3.41$3.6621.41K
Sep 28, 2026$3.60$3.60$3.495$3.5010.41K
Sep 25, 2026$3.72$3.72$3.60$3.672.55K
Sep 24, 2026$3.61$3.99$3.61$3.775.82K
Sep 23, 2026$3.83$3.98$3.50$3.5515.66K
Sep 22, 2026$3.7799$3.9999$3.75$3.7811.83K
Sep 21, 2026$3.875$3.90$3.6501$3.7811.4K
Sep 18, 2026$3.85$3.92$3.8001$3.913.09K
Sep 17, 2026$3.86$3.94$3.7219$3.7510.67K
Sep 16, 2026$3.60$3.85$3.60$3.8510.51K
Sep 15, 2026$3.85$3.85$3.50$3.5014.57K
Sep 14, 2026$4.02$4.02$3.83$3.8633K
Sep 11, 2026$4.15$4.33$4.05$4.0522.3K
Sep 10, 2026$4.46$4.46$4.11$4.1156.87K

Latest ATHE news

The latest Smart Investors Daily articles mentioning ATHE.

Stock researchCompany · Overview

ATHE research

Overview

Company profile and research snapshot.

Company profile

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ATHE recent ratings
DateFirmRatingTarget
Aug 12, 2026CANACCORD GENUITYBuy—
Jun 9, 2026CANACCORD GENUITYBuy—
Jun 8, 2026CANACCORD GENUITYBuy—
Jan 5, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 5, 2026

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3 MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments f

Yahoo · Sep 23, 2026

Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference

Alterity Therapeutics CEO David Stamler talked with Proactive at the ASX Small and Mid-Cap Conference about how it’s developing disease modifying therapies, the neurodegenerative diseases market and what’s next for the company. Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. #AlterityTherapeuticsLimited #ProactiveInvestors #DavidStamler #NeurodegenerativeDisease #Biotechnology

Yahoo · Sep 3, 2026

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States. A link to the live

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By